Price T Rowe Associates Inc Bio Atla, Inc. Transaction History

Price T Rowe Associates Inc

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$1.88 - $3.46 $24,047 - $44,256	12,791 New	12,791 $45,000
Q1 2021 May 17, 2021	SELL	$32.41 - $70.91 $20.7 Million - $45.3 Million	-638,480 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$31.02 - $35.16 $19.8 Million - $22.4 Million	638,480 New	638,480 $21.7 Million

23.4M

30.8K

57K

Ticker BCAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,304,100
Market Cap $11.6M
Description
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

Stay updated on Price T Rowe Associates Inc with notifications on news.